Search Result

Results for "

amyloid-β peptide

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amyloid-β (37) Autophagy (2) Beta-secretase (2) Cholinesterase (ChE) (5) Drug Derivative (1) Fluorescent Dye (1) Glycosidase (1) Interleukin Related (1) nAChR (2) NOD-like Receptor (NLR) (1) Reactive Oxygen Species (ROS) (3) Reference Standards (2) γ-secretase (1)
By Research Areas:	Cancer (2) Inflammation/Immunology (1) Neurological Disease (48)

Inhibitors & Agonists

Fluorescent Dyes

Peptides

Inhibitory Antibodies

Natural
Products

Antibodies

Targets Recommended: Amyloid-β RXFP Receptor Formyl Peptide Receptor (FPR) Peptide-Drug Conjugates (PDCs) Natriuretic Peptide Receptor (NPR) Connective Peptide CGRP Receptor

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N2332A

Methyllycaconitine citrate Maximum Cited Publications 43 Publications Verification MLA citrate	nAChR	Neurological Disease
Methyllycaconitine (MLA) citrate is a potent, selective, CNS-penetrant, competitive α7nAChR antagonist. Methyllycaconitine citrate alleviates amyloid-β peptides-induced cytotoxicity in SH-SY5Y cells. Methyllycaconitine citrate prevents methamphetamine-induced effects in mouse striatum. Methyllycaconitine citrate can be used for neurological disease research, such as Alzheimer’s disease .

HY-P1362

β-Amyloid (42-1), human 1 Publications Verification amyloid β peptide (42-1)(human)	Amyloid-β	Neurological Disease
β-Amyloid (42-1), human is the inactive form of Amyloid β Peptide (1-42). Its active form, β-Amyloid (1-42), may play a key role in the pathogenesis of Alzheimer's disease .

HY-P99317

Solanezumab LY-2062430	Amyloid-β	Neurological Disease
Solanezumab (LY-2062430) is a humanized monoclonal IgG1 antibody directed against the mid-domain of the *amyloid-β* (Aβ) peptide. Solanezumab binds to the mid-domain of monomeric amyloid-beta to slow brain amyloid accumulation. Solanezumab can be used for the research of Alzheimer’s disease .

HY-100200

SMER28 2 Publications Verification	Autophagy	Cancer
SMER28 is a positive regulator of autophagy acting via an mTOR-independent mechanism. SMER28 prevents the accumulation of amyloid beta peptide.

HY-125616

Biotinoyl tripeptide-1 Biotinyl-GHK; Bio-GHK	Amyloid-β Reactive Oxygen Species (ROS)	Neurological Disease
Biotinoyl tripeptide-1 (Biotinyl-GHK) is a biotinylating reagent linked to a GHK (glycyl-L-histidyl-L-lysine) tripeptide. Biotin tripeptide-1 is a bioactive peptide with hair care (improves the appearance and feel of hair) and hair growth effects. Biotinoyl tripeptide-1 has a certain affinity for streptavidin. Biotinoyl tripeptide-1 inhibits the production of ROS and has antioxidant effects. Biotinoyl tripeptide-1 reduces the production of carbonylated *amyloid-β* (Aβ) and inhibits Aβ aggregation. Biotinoyl tripeptide-1 can be used in the study of neurodegenerative diseases .

HY-N0061

Ethyl ferulate 3 Publications Verification	Reactive Oxygen Species (ROS)	Neurological Disease
Ethyl ferulate, a naturally lipophilic derivative of ferulic acid originally derived from Rhizoma Chuanxiong, induces heme oxygenase-1 (HO-1) and protects rat neurons against oxidative stress . Ethyl ferulate also protects neurons against amyloid β peptide (1-42)-induced oxidative stress and neurotoxicity .

HY-17631A

Edonerpic maleate T-817 maleate; T-817MA	Amyloid-β	Neurological Disease
Edonerpic maleate is a novel neurotrophic agent which can inhibit **amyloid-β peptides** (Aβ).

HY-P5124

*β-Amyloid* peptide(16-20)** KLVFF	Amyloid-β	Neurological Disease
β-Amyloid peptide(16-20) is a amino acid sequences (KLVFF) of *Amyloid-β* (Abeta). β-Amyloid peptide(16-20) is an effective inhibitor of Abeta fibril formation, with RG-/-GR-NH₂ residues added at N- and C-terminal ends to aid solubility) .

HY-N2319

Dihydroergocristine mesylate 1 Publications Verification DHEC mesylate	Amyloid-β	Neurological Disease
Dihydroergocristine mesylate (DHEC mesylate) is a inhibitor of γ-secretase (GSI), reduces the production of the Alzheimer's disease *amyloid-β* peptides, binds directly to γ-secretase and Nicastrin with equilibrium dissociation constants (K_d) of 25.7 nM and 9.8 μM, respectively .

HY-P5905

*Citrullinated amyloid-β* (1-42) peptide (human)** Citrullinated Aβ (1-42); Citrullinated Aβ42	Amyloid-β	Neurological Disease
Citrullinated amyloid-β (1-42) peptide (human) (Citrullinated Aβ (1-42)) is a modified form of β-Amyloid (1-42) (HY-P1363) with a citrullination at the Arg5 site. Compared to the unmodified β-Amyloid (1-42), its formation of soluble low-molecular-weight oligomers is enhanced, the rate of fibril formation is reduced, and like unmodified Aβ42, it forms protofibrils comprised of parallel β-sheets .

HY-P1962

β-Secretase inhibitor [Asn670, Sta671, Val672]-amyloid β peptide (662-675)	Beta-secretase	Neurological Disease
β-Secretase inhibitor ([Asn670, Sta671, Val672]-Amyloid β Peptide (662-675)) is a β-secretase and BACE1 inhibitor (IC₅₀: 25 nM for β-secretase) .

HY-P10040

(Gln22)β-Amyloid (1-40) human	Amyloid-β	Neurological Disease
(Gln22)β-Amyloid (1-40) human is an amyloid beta protein (Aβ)-containing peptide used in Alzheimer's disease research .

HY-P1047

β-Sheet Breaker Peptide iAβ5 [Pro18, Asp21] β-amyloid (17-21)	Amyloid-β	Neurological Disease
β-Sheet Breaker Peptide iAβ5 is an effective brain amyloid-β (Abeta) degrader. Abeta deposits are associated with Alzheimer's disease (AD), and the related toxicity arises from its β-sheet conformation and aggregation. β-Sheet Breaker Peptide iAβ5 can repeatedly induce the degradation of fibrillary amyloid deposits in vivo. Therefore, β-Sheet Breaker Peptide iAβ5 can prevent and/or reverse neuronal contraction caused by Abeta and reduce the range of interleukin IL-1beta positive microglial-like cells around Abeta deposits. β-Sheet Breaker Peptide iAβ5 can reduce the size and/or number of brain amyloid plaques in AD. β-Sheet Breaker Peptide iAβ5 is labeled with a hydrophobic benzyl alcohol (HBA) tag and shows a bright blue color under acidic conditions, which can be used for quantitative determination.

HY-N8161

Kaempferol-3,7-di-O-β-glucoside Kaempferol 3,7-diglucoside	Glycosidase Cholinesterase (ChE)	Neurological Disease
Kaempferol-3,7-di-O-β-glucoside (Kaempferol 3,7-diglucoside), a flavonol, possesses enzyme inhibition property towards α-amylase, α-glucosidase and Acetylcholinesterase. Kaempferol-3,7-di-O-β-glucoside protects differentiating neuronal cells, SH-SY5Y from Amyloid β peptide-induced injury. Kaempferol-3,7-di-O-β-glucoside has the potential for Alzheimer's research .

HY-P1362F

Cy5-β-Amyloid (42-1), human Tris Cy5-amyloid β peptide (42-1)(human) Tris	Amyloid-β	Neurological Disease
Cy5-β-Amyloid (42-1), human is a Cy5 fluorescently-labelled β-Amyloid (42-1, human) peptide (λ_ex= 633 nm and λ_em= 670 nm) .

HY-P3244

D-KLVFFA	Amyloid-β	Neurological Disease
D-KLVFFA is the inhibitor of Amyloid-β assembly, with the IC₅₀ of 2.6 μM, that can be used in Alzheimer's disease study .

HY-P4885

*Glp-amyloid-β* (3-40) peptide (human)** AβpE3-40	Amyloid-β	Neurological Disease
Glp-Amyloid-β (3-40) Peptide (human) (AβpE3-40) is a minor amounts of pyroglutamate-modified Aβ isolated from from 24-month-old Amyloid precursor protein (APP) transgenic Mice .

HY-P1517

β-Amyloid (31-35)	Amyloid-β	Neurological Disease
β-Amyloid (31-35) is the shortest sequence of native Amyloid-β peptide that retains neurotoxic activity.

HY-P2549

Biotin-β-Amyloid (1-40)	Fluorescent Dye	Neurological Disease
Biotin-β-Amyloid (1-40) is a N-terminal-labelled biotinylated amyloid-β-(1-40) peptide.

HY-P5906

*Citrullinated amyloid-β* (1-40) peptide (human)** Citrullinated Aβ (1-40); Citrullinated Aβ40	Amyloid-β	Neurological Disease
Citrullinated amyloid-β (1-40) peptide (human) (Citrullinated Aβ (1-40)) is a modified form of β-Amyloid (1-40) (HY-P0265) with a citrullination at the Arg5 site. Citrullinated amyloid-β (1-40) peptide (human) exhibits increased transient formation of soluble oligomers and insoluble aggregates composed of distorted parallel β-sheets compared with unmodified β-Amyloid (1-40) .

HY-P1362A

β-Amyloid (42-1), human TFA amyloid β peptide (42-1)(human) TFA	Amyloid-β	Neurological Disease
β-Amyloid (42-1), human TFA is the inactive form of Amyloid β Peptide (1-42). β-Amyloid (42-1), human TFA is a 42-amino acid peptide which plays a key role in the pathogenesis of Alzheimer disease .

HY-P1522

β-Amyloid (29-40) amyloid beta-protein(29-40)	Amyloid-β	Neurological Disease
β-Amyloid (29-40) is a fragment of Amyloid-β peptide.

HY-P1053

β-Amyloid (10-20)	Amyloid-β	Neurological Disease
β-Amyloid (10-20) is a fragment of Amyloid-β peptide and maybe used in the research of neurological disease .

HY-P10613

RERMS	Amyloid-β	Neurological Disease
RERMS are bioactive peptides produced from the active regions of *amyloid-β* and A4 protein precursors that promote fibroblast growth and can be used in the study of neurodegenerative diseases .

HY-103538

JLK-6	Amyloid-β	Neurological Disease
JLK-6 markedly reduce the production of amyloid β-peptide (Aβ) by amyloid-β Precursor protein (APP) expressing HEK293 cells by affecting the γ-secretase cleavage of APP, with no effect on the cleavage of the Notch receptor .

HY-P10040A

(Gln22)β-Amyloid (1-40) human TFA	Amyloid-β	Neurological Disease
(Gln22)β-Amyloid (1-40) (human) TFA is an amyloid beta protein (Aβ)-containing peptide used in Alzheimer's disease research .

HY-P4391

(Asp37)-Amyloid β-Protein (1-42)	Amyloid-β	Neurological Disease
(Asp37)-Amyloid β-Protein (1-42) is the G37D mutant of wild-type Amyloid-beta (1-42) peptide .

HY-W440555

4-Sulfocalix[4]arene para-Sulfonatocalix[n]arene	Amyloid-β	Neurological Disease
4-Sulfocalix[4]arene (para-Sulfonatocalix[n]arene) is a amyloid-beta 42 binder with a K_d of 5.39 M. 4-Sulfocalix[4]arene can inhibit amyloid β-peptide fibrillation and reduce amyloid cytotoxicity .

HY-P10823

RI-OR2	Amyloid-β	Neurological Disease
RI-OR2, a retro-inverso peptide, is an amyloid-β (Aβ) oligomerization inhibitor. RI-OR2 binds to immobilized β-Amyloid (1-42) (HY-P1363A) monomers and fibrils, with an apparent K_d of 9-12 μM, and also acted as an inhibitor of Aβ(1-42) fibril extension .

HY-P1524

β-Amyloid (1-14),mouse,rat	Amyloid-β	Neurological Disease
β-Amyloid (1-14),mouse,rat is a 1 to 14 fragment of Amyloid-β peptide.

HY-P1521

β-Amyloid (15-21) Beta-amyloid (15-21)	Amyloid-β	Neurological Disease
β-amyloid (15-21) is a fragment of Amyloid-β peptide, maybe used in the research of neurological disease.

HY-P1510

β-Amyloid (1-11)	Amyloid-β	Neurological Disease
β-Amyloid (1-11) is a fragment of Amyloid-β peptide, maybe used in the research of neurological disease.

HY-163441

BChE-IN-31	Cholinesterase (ChE)	Neurological Disease
BChE-IN-31 (Compound 14d) is a selective BChE inhibitor with an IC₅₀ of 65 nM. BChE-IN-31 inhibits the self-induced aggregation of neurotoxic amyloid-β (Aβ) peptide .

HY-121191

Bisnorcymserine N1,N8-Bisnorcymserine; (-)-Bisnorcymserine	Cholinesterase (ChE)	Neurological Disease
Bisnorcymserine ((-)-Bisnorcymserine) is an inhibitor for butyrylcholinesterase (BChE) with an IC₅₀ of 0.228 nM. Bisnorcymserine reduces the levels of amyloid-β peptide (Aβ), exhibits ameliorates the Alzheimer’s Disease in elderly rat models. Bisnorcymserine is blood-brain barrier penetrate .

HY-P2551

Biotin-β-Amyloid (17-40)	Amyloid-β	Neurological Disease
Biotin-β-Amyloid (17-40) is a N-terminal-labelled biotinylated amyloid-β(1-40) peptide. β-Amyloid (17-40) is a 24-residue fragment of the Aβ protein via post-translational processing of amyloid precursor protein (APP) .

HY-P3275

β-Amyloid (17-40) Aβ(17-40)	Amyloid-β	Neurological Disease
β-Amyloid (17-40) (Aβ(17-40)) is a fragment of Amyloid-β peptide that has shown neurotoxic activities in SH-SY5Y and IMR-32 cells. β-Amyloid (17-40) can be used for the research of neurological disease .

HY-N2319R

Dihydroergocristine mesylate (Standard) DHEC mesylate (Standard)	Reference Standards Amyloid-β	Neurological Disease
Dihydroergocristine (mesylate) (Standard) is the analytical standard of Dihydroergocristine (mesylate). This product is intended for research and analytical applications. Dihydroergocristine mesylate (DHEC mesylate) is a inhibitor of γ-secretase (GSI), reduces the production of the Alzheimer's disease *amyloid-β* peptides, binds directly to γ-secretase and Nicastrin with equilibrium dissociation constants (K_d) of 25.7 nM and 9.8 μM, respectively .

HY-162832

Amyloid-β-IN-1	Amyloid-β	Neurological Disease
Amyloid-β-IN-1 (compound 13) is a synthetic peptide containing the hydrophobic C-terminal region "VVIA-NH2" and its reverse sequence "AIVV-NH2" of Aβ₄₂, which is an Aβ inhibitor. Amyloid-β-IN-1 can inhibit Aβ aggregation and has neuroprotective effects .

HY-13325

Aβ aggregation modulator-1	Drug Derivative Amyloid-β	Neurological Disease
Aβ aggregation modulator-1 is a stimulator of *amyloid-β* (Aβ) fibrillogenesis. Aβ aggregation modulator-1 binds hydrophobic residues in Aβ peptides and stabilizes β-sheet-rich protofibrils and fibrils. Aβ aggregation modulator-1 accelerates Aβ polymerization and reduces concentrations of small, toxic Aβ oligomers in heterogeneous aggregation reactions. Aβ aggregation modulator-1 suppresses long-term potentiation (LTP) inhibition by Aβ oligomers in hippocampal brain slices. Aβ aggregation modulator-1 can be used for the study of Alzheimer's disease (AD) .

HY-157296

AChE-IN-47	Cholinesterase (ChE)	Neurological Disease
AChE-IN-47 (compound g17) is a AChE inhibitor with the IC₅₀ of 0.24 μM. AChE-IN-47 inhibits amyloid β peptides self-aggregation. AChE-IN-47 displays neuroprotective effects and effectively suppresses the intracellular accumulation of reactive oxygen species .

HY-100740A

Lanabecestat hydrochloride AZD-3293 hydrochloride; LY3314814 hydrochloride	Beta-secretase	Neurological Disease
Lanabecestat (AZD3293; LY3314814) hydrochloride is a potent BACE1 inhibitor that has been investigated for its potential as a modifying treatment for Alzheimer's disease. Lanabecestat (hydrochloride) demonstrated significant dose- and time-dependent reductions in concentrations of amyloid beta peptides in plasma, cerebrospinal fluid, and brain. Lanabecestat (hydrochloride) was also shown to produce reductions in Aβ neuritic plaque burden without demonstrating clinical benefits or slowing the progression of Alzheimer's disease pathophysiology.

HY-172782

BuChE-IN-20	Cholinesterase (ChE) Amyloid-β Interleukin Related Reactive Oxygen Species (ROS) NOD-like Receptor (NLR)	Neurological Disease Inflammation/Immunology
BuChE-IN-20 is a selective butyrylcholinesterase (hBuChE) inhibitor (IC₅₀ = 0.13 μM) with BBB permeability. BuChE-IN-20 is a L-Tryptophan derivative. BuChE-IN-20 possesses neuroprotective properties by inhibiting the production of nitric oxide (NO) and lowering the levels of ROS. BuChE-IN-20 is proficient in inhibiting the self-aggregation of amyloid-beta (Aβ) peptides. BuChE-IN-20 can be used in research for Alzheimer’s disease .

HY-182328

BTA-EG6	Amyloid-β	Neurological Disease
BTA-EG6 is a brain-penetrant aggregated *amyloid-β* (Aβ) peptide binder with a K_d of 290 nM for Aβ1-42. BTA-EG6 binds to aggregated Aβ and forms protein-resistive coatings that block interactions between Aβ and catalase. BTA-EG6 protects neuroblastoma cells from Aβ-induced toxicity and oxidative stress, and inhibits Aβ-induced increases in cellular hydrogen peroxide (H₂O₂) levels. BTA-EG6 can be used for the research of alzheimer’s disease (AD) .

HY-N2332

Methyllycaconitine MLA	nAChR	Neurological Disease
Methyllycaconitine (MLA) is a potent, selective, CNS-penetrant, competitive α7nAChR antagonist. Methyllycaconitine alleviates amyloid-β peptides-induced cytotoxicity in SH-SY5Y cells. Methyllycaconitine prevents methamphetamine-induced effects in mouse striatum. Methyllycaconitine can be used for neurological disease research, such as Alzheimer’s disease .

HY-P991534

PF-04382923	Amyloid-β	Neurological Disease
PF-04382923 is a humanized IgG2Δa monoclonal antibody. PF-04382923 binds with high affinity to the free C-terminal regions of the *amyloid-β* peptides Aβ1-40 and Aβ1-42. PF-04382923 is indicated for the study of geographic atrophy (GA) associated with dry age-related macular degeneration (ARMD) .

HY-P10611

[D-Ser14]-Humanin	Amyloid-β	Neurological Disease
[D-Ser14]-Humanin is a bioactive peptide in which the Ser14 residue of Humanin (HY-P1928) is changed from L-form to D-form. [D-Ser14]-Humanin has potent inhibitory activity against the fibrillation of *amyloid-β. Humanin (HY-P1928) inhibits the aging-related death of various cells caused by amyloid* fibrils and oxidative stress, and [D-Ser14]-Humanin has better cell protection activity than Humanin (HY-P1928). [D-Ser14]-Humanin can be used in the study of Alzheimer's disease .

HY-100200R

SMER28 (Standard)	Autophagy Reference Standards	Cancer
SMER28 (Standard) is the analytical standard of SMER28 (HY-100200). This product is intended for research and analytical applications. SMER28 is a positive regulator of autophagy acting via an mTOR-independent mechanism. SMER28 prevents the accumulation of amyloid beta peptide.

HY-118972

TPI-1917-49	Amyloid-β	Neurological Disease
TPI-1917-49 is an agent that can cross the blood-brain barrier and reduce amyloid β (Aβ). TPI-1917-49 reduces the production of Aβ peptide segments by promoting the non-amyloidogenic pathway of amyloid precursor protein (APP) (increasing the generation of sAPPα mediated by α-secretase). TPI-1917-49 reduces amyloid plaques in mouse models. TPI-1917-49 can be used in Alzheimer's disease research .

HY-P11677

CPO_Aβ17-21P		Neurological Disease
CPO_Aβ17-21P is a apoE/Aβ interaction inhibitor with an IC₅₀ of 1.02 nM. CPO_Aβ17-21P significantly inhibits ApoE4-mediated aggregation of Aβ40 and Aβ42. CPO_Aβ17-21P significantly improves cognitive function and comprehensively alleviates Alzheimer's disease (AD)-related pathologies in mouse models. CPO_Aβ17-21P is applicable to the research of AD .

HY-18326

BMS-869780	γ-secretase Amyloid-β	Neurological Disease
BMS-869780 is an orally active non-acidic γ-secretase (γ-secretase) modulator. BMS-869780 regulates the activity of γ-secretase, thereby altering the production profile of β-amyloid proteins. When acting alone, it changes the relative levels of specific β-amyloid subtypes without inhibiting the total production of β-amyloid proteins. BMS-869780 exerts a synergistic effect with γ-secretase modulators of the acidic structural class to inhibit the total production of β-amyloid proteins in cell cultures .

Cat. No.	Product Name	Target	Research Area

HY-P1362

β-Amyloid (42-1), human 1 Publications Verification amyloid β peptide (42-1)(human)	Amyloid-β	Neurological Disease
β-Amyloid (42-1), human is the inactive form of Amyloid β Peptide (1-42). Its active form, β-Amyloid (1-42), may play a key role in the pathogenesis of Alzheimer's disease .

HY-125616

Biotinoyl tripeptide-1 Biotinyl-GHK; Bio-GHK	Amyloid-β Reactive Oxygen Species (ROS)	Neurological Disease
Biotinoyl tripeptide-1 (Biotinyl-GHK) is a biotinylating reagent linked to a GHK (glycyl-L-histidyl-L-lysine) tripeptide. Biotin tripeptide-1 is a bioactive peptide with hair care (improves the appearance and feel of hair) and hair growth effects. Biotinoyl tripeptide-1 has a certain affinity for streptavidin. Biotinoyl tripeptide-1 inhibits the production of ROS and has antioxidant effects. Biotinoyl tripeptide-1 reduces the production of carbonylated *amyloid-β* (Aβ) and inhibits Aβ aggregation. Biotinoyl tripeptide-1 can be used in the study of neurodegenerative diseases .

HY-P5124

*β-Amyloid* peptide(16-20)** KLVFF	Amyloid-β	Neurological Disease
β-Amyloid peptide(16-20) is a amino acid sequences (KLVFF) of *Amyloid-β* (Abeta). β-Amyloid peptide(16-20) is an effective inhibitor of Abeta fibril formation, with RG-/-GR-NH₂ residues added at N- and C-terminal ends to aid solubility) .

HY-P5905

*Citrullinated amyloid-β* (1-42) peptide (human)** Citrullinated Aβ (1-42); Citrullinated Aβ42	Amyloid-β	Neurological Disease
Citrullinated amyloid-β (1-42) peptide (human) (Citrullinated Aβ (1-42)) is a modified form of β-Amyloid (1-42) (HY-P1363) with a citrullination at the Arg5 site. Compared to the unmodified β-Amyloid (1-42), its formation of soluble low-molecular-weight oligomers is enhanced, the rate of fibril formation is reduced, and like unmodified Aβ42, it forms protofibrils comprised of parallel β-sheets .

HY-P1962

β-Secretase inhibitor [Asn670, Sta671, Val672]-amyloid β peptide (662-675)	Beta-secretase	Neurological Disease
β-Secretase inhibitor ([Asn670, Sta671, Val672]-Amyloid β Peptide (662-675)) is a β-secretase and BACE1 inhibitor (IC₅₀: 25 nM for β-secretase) .

HY-P10040

(Gln22)β-Amyloid (1-40) human	Amyloid-β	Neurological Disease
(Gln22)β-Amyloid (1-40) human is an amyloid beta protein (Aβ)-containing peptide used in Alzheimer's disease research .

HY-P1047

β-Sheet Breaker Peptide iAβ5 [Pro18, Asp21] β-amyloid (17-21)	Amyloid-β	Neurological Disease
β-Sheet Breaker Peptide iAβ5 is an effective brain amyloid-β (Abeta) degrader. Abeta deposits are associated with Alzheimer's disease (AD), and the related toxicity arises from its β-sheet conformation and aggregation. β-Sheet Breaker Peptide iAβ5 can repeatedly induce the degradation of fibrillary amyloid deposits in vivo. Therefore, β-Sheet Breaker Peptide iAβ5 can prevent and/or reverse neuronal contraction caused by Abeta and reduce the range of interleukin IL-1beta positive microglial-like cells around Abeta deposits. β-Sheet Breaker Peptide iAβ5 can reduce the size and/or number of brain amyloid plaques in AD. β-Sheet Breaker Peptide iAβ5 is labeled with a hydrophobic benzyl alcohol (HBA) tag and shows a bright blue color under acidic conditions, which can be used for quantitative determination.

HY-P1362F

Cy5-β-Amyloid (42-1), human Tris Cy5-amyloid β peptide (42-1)(human) Tris	Amyloid-β	Neurological Disease
Cy5-β-Amyloid (42-1), human is a Cy5 fluorescently-labelled β-Amyloid (42-1, human) peptide (λ_ex= 633 nm and λ_em= 670 nm) .

HY-P3244

D-KLVFFA	Amyloid-β	Neurological Disease
D-KLVFFA is the inhibitor of Amyloid-β assembly, with the IC₅₀ of 2.6 μM, that can be used in Alzheimer's disease study .

HY-P4885

*Glp-amyloid-β* (3-40) peptide (human)** AβpE3-40	Amyloid-β	Neurological Disease
Glp-Amyloid-β (3-40) Peptide (human) (AβpE3-40) is a minor amounts of pyroglutamate-modified Aβ isolated from from 24-month-old Amyloid precursor protein (APP) transgenic Mice .

HY-P1517

β-Amyloid (31-35)	Amyloid-β	Neurological Disease
β-Amyloid (31-35) is the shortest sequence of native Amyloid-β peptide that retains neurotoxic activity.

HY-P2549

Biotin-β-Amyloid (1-40)	Fluorescent Dye	Neurological Disease
Biotin-β-Amyloid (1-40) is a N-terminal-labelled biotinylated amyloid-β-(1-40) peptide.

HY-P5906

*Citrullinated amyloid-β* (1-40) peptide (human)** Citrullinated Aβ (1-40); Citrullinated Aβ40	Amyloid-β	Neurological Disease
Citrullinated amyloid-β (1-40) peptide (human) (Citrullinated Aβ (1-40)) is a modified form of β-Amyloid (1-40) (HY-P0265) with a citrullination at the Arg5 site. Citrullinated amyloid-β (1-40) peptide (human) exhibits increased transient formation of soluble oligomers and insoluble aggregates composed of distorted parallel β-sheets compared with unmodified β-Amyloid (1-40) .

HY-P1362A

β-Amyloid (42-1), human TFA amyloid β peptide (42-1)(human) TFA	Amyloid-β	Neurological Disease
β-Amyloid (42-1), human TFA is the inactive form of Amyloid β Peptide (1-42). β-Amyloid (42-1), human TFA is a 42-amino acid peptide which plays a key role in the pathogenesis of Alzheimer disease .

HY-P1522

β-Amyloid (29-40) amyloid beta-protein(29-40)	Amyloid-β	Neurological Disease
β-Amyloid (29-40) is a fragment of Amyloid-β peptide.

HY-P1053

β-Amyloid (10-20)	Amyloid-β	Neurological Disease
β-Amyloid (10-20) is a fragment of Amyloid-β peptide and maybe used in the research of neurological disease .

HY-P10613

RERMS	Amyloid-β	Neurological Disease
RERMS are bioactive peptides produced from the active regions of *amyloid-β* and A4 protein precursors that promote fibroblast growth and can be used in the study of neurodegenerative diseases .

HY-P10040A

(Gln22)β-Amyloid (1-40) human TFA	Amyloid-β	Neurological Disease
(Gln22)β-Amyloid (1-40) (human) TFA is an amyloid beta protein (Aβ)-containing peptide used in Alzheimer's disease research .

HY-P4391

(Asp37)-Amyloid β-Protein (1-42)	Amyloid-β	Neurological Disease
(Asp37)-Amyloid β-Protein (1-42) is the G37D mutant of wild-type Amyloid-beta (1-42) peptide .

HY-P10823

RI-OR2	Amyloid-β	Neurological Disease
RI-OR2, a retro-inverso peptide, is an amyloid-β (Aβ) oligomerization inhibitor. RI-OR2 binds to immobilized β-Amyloid (1-42) (HY-P1363A) monomers and fibrils, with an apparent K_d of 9-12 μM, and also acted as an inhibitor of Aβ(1-42) fibril extension .

HY-P1524

β-Amyloid (1-14),mouse,rat	Amyloid-β	Neurological Disease
β-Amyloid (1-14),mouse,rat is a 1 to 14 fragment of Amyloid-β peptide.

HY-P1521

β-Amyloid (15-21) Beta-amyloid (15-21)	Amyloid-β	Neurological Disease
β-amyloid (15-21) is a fragment of Amyloid-β peptide, maybe used in the research of neurological disease.

HY-P1510

β-Amyloid (1-11)	Amyloid-β	Neurological Disease
β-Amyloid (1-11) is a fragment of Amyloid-β peptide, maybe used in the research of neurological disease.

HY-P2551

Biotin-β-Amyloid (17-40)	Amyloid-β	Neurological Disease
Biotin-β-Amyloid (17-40) is a N-terminal-labelled biotinylated amyloid-β(1-40) peptide. β-Amyloid (17-40) is a 24-residue fragment of the Aβ protein via post-translational processing of amyloid precursor protein (APP) .

HY-P3275

β-Amyloid (17-40) Aβ(17-40)	Amyloid-β	Neurological Disease
β-Amyloid (17-40) (Aβ(17-40)) is a fragment of Amyloid-β peptide that has shown neurotoxic activities in SH-SY5Y and IMR-32 cells. β-Amyloid (17-40) can be used for the research of neurological disease .

HY-P10611

[D-Ser14]-Humanin	Amyloid-β	Neurological Disease
[D-Ser14]-Humanin is a bioactive peptide in which the Ser14 residue of Humanin (HY-P1928) is changed from L-form to D-form. [D-Ser14]-Humanin has potent inhibitory activity against the fibrillation of *amyloid-β. Humanin (HY-P1928) inhibits the aging-related death of various cells caused by amyloid* fibrils and oxidative stress, and [D-Ser14]-Humanin has better cell protection activity than Humanin (HY-P1928). [D-Ser14]-Humanin can be used in the study of Alzheimer's disease .

HY-P11677

CPO_Aβ17-21P		Neurological Disease
CPO_Aβ17-21P is a apoE/Aβ interaction inhibitor with an IC₅₀ of 1.02 nM. CPO_Aβ17-21P significantly inhibits ApoE4-mediated aggregation of Aβ40 and Aβ42. CPO_Aβ17-21P significantly improves cognitive function and comprehensively alleviates Alzheimer's disease (AD)-related pathologies in mouse models. CPO_Aβ17-21P is applicable to the research of AD .

Cat. No.	Product Name	Target	Research Area	Image

HY-P99317

Solanezumab LY-2062430	Amyloid-β	Neurological Disease
Solanezumab (LY-2062430) is a humanized monoclonal IgG1 antibody directed against the mid-domain of the *amyloid-β* (Aβ) peptide. Solanezumab binds to the mid-domain of monomeric amyloid-beta to slow brain amyloid accumulation. Solanezumab can be used for the research of Alzheimer’s disease .

HY-P991534

PF-04382923	Amyloid-β	Neurological Disease
PF-04382923 is a humanized IgG2Δa monoclonal antibody. PF-04382923 binds with high affinity to the free C-terminal regions of the *amyloid-β* peptides Aβ1-40 and Aβ1-42. PF-04382923 is indicated for the study of geographic atrophy (GA) associated with dry age-related macular degeneration (ARMD) .

Host:	Mouse (2) Rabbit (5)
Reactivity:	Human (7) Rat (3) Mouse (1)
Application:	IHC-P (5) ICC/IF (3) IF-Tissue (2) IP (3) IHC-F (2) WB (5) ELISA (1)
Isotype:	IgG (5) IgG2b (2)
Conjugation:	Non-conjugated (7)
Clonality:	Monoclonal (4) Recombinant (2)
Modification:	Phosphorylated (1) Unmodified (3)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P86747

	beta-Amyloid 1-42 Antibody (YA6439) beta-amyloid(1-42); A4; AAA; ABETA; ABPP; AD1; Alzheimers Disease amyloid Protein; amyloid B; amyloid beta A4 Protein Precursor; amyloid beta; amyloid of Aging and Alzheimer Disease; APP; APPI; B amyloid; beta APP; Cerebral Vascular amyloid peptide; CTFgamma; CVAP; PN II; PN2; PreA4; Protease nexin II; A beta; amyloid 1-42.Aβ	WB, IHC-P, IHC-F, IF-Tissue	Human
	beta-Amyloid(1-42) Antibody (YA6439) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to beta-Amyloid(1-42).

HY-P86747A

	beta-Amyloid 1-42 Antibody (YA6439)(PBS only) beta-amyloid(1-42); A4; AAA; ABETA; ABPP; AD1; Alzheimers Disease amyloid Protein; amyloid B; amyloid beta A4 Protein Precursor; amyloid beta; amyloid of Aging and Alzheimer Disease; APP; APPI; B amyloid; beta APP; Cerebral Vascular amyloid peptide; CTFgamma; CVAP; PN II; PN2; PreA4; Protease nexin II; A beta; amyloid 1-42.Aβ	WB, IHC-P, IHC-F, IF-Tissue	Human
	beta-Amyloid(1-42) Antibody (YA6439) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to beta-Amyloid(1-42).

HY-P81385

	Amyloid Precursor Protein Antibody (YA1130) APP; A4; AD1; amyloid beta A4 protein; ABPP; APPI; APP; Alzheimer disease amyloid protein; Cerebral vascular amyloid peptide; CVAP; PreA4; Protease nexin-II; PN-II	IHC-P	Human
	Amyloid Precursor Protein Antibody (YA1130) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Amyloid Precursor Protein.

HY-P86422

	beta-Amyloid Antibody (YA6114) APP; A4; AD1; amyloid beta A4 protein; ABPP; APPI; APP; Alzheimer disease amyloid protein; Cerebral vascular amyloid peptide; CVAP; PreA4; Protease nexin-II; PN-II; Aβ	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	beta-Amyloid Antibody (YA6114) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to beta-Amyloid.

HY-P81385A

	Amyloid Precursor Protein Antibody (YA1130)(PBS only) APP; A4; AD1; amyloid beta A4 protein; ABPP; APPI; APP; Alzheimer disease amyloid protein; Cerebral vascular amyloid peptide; CVAP; PreA4; Protease nexin-II; PN-II	IHC-P	Human
	Amyloid Precursor Protein Antibody (YA1130) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Amyloid Precursor Protein.

HY-P82823

	Phospho-Amyloid Precursor Protein (Thr743) Antibody (YA2568) APP; A4; AD1; amyloid beta A4 protein; ABPP; APPI; APP; Alzheimer disease amyloid protein; Cerebral vascular amyloid peptide; CVAP; PreA4; Protease nexin-II; PN-II	WB, ICC/IF, IP	Human, Rat
	Phospho-Amyloid Precursor Protein (Thr743) Antibody (YA2568) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-Amyloid Precursor Protein (Thr743).

HY-P82823A

	Phospho-Amyloid Precursor Protein (Thr743) Antibody (YA2568)(PBS only) APP; A4; AD1; amyloid beta A4 protein; ABPP; APPI; APP; Alzheimer disease amyloid protein; Cerebral vascular amyloid peptide; CVAP; PreA4; Protease nexin-II; PN-II	WB, ICC/IF, IP	Human, Rat
	Phospho-Amyloid Precursor Protein (Thr743) Antibody (YA2568) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-Amyloid Precursor Protein (Thr743).

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

amyloid-β peptide

Inhibitors & Agonists

Fluorescent Dyes

Peptides

Inhibitory Antibodies

NaturalProducts

Antibodies

Natural
Products